Lee Danner & Bass Inc. Sells 303 Shares of Medtronic PLC (MDT)

Lee Danner & Bass Inc. cut its position in shares of Medtronic PLC (NYSE:MDT) by 0.5% in the first quarter, HoldingsChannel reports. The firm owned 60,044 shares of the medical technology company’s stock after selling 303 shares during the period. Lee Danner & Bass Inc.’s holdings in Medtronic were worth $5,469,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of MDT. Tributary Capital Management LLC purchased a new stake in shares of Medtronic during the 4th quarter worth about $27,000. Cordasco Financial Network purchased a new stake in shares of Medtronic during the 1st quarter worth about $27,000. Pin Oak Investment Advisors Inc. raised its stake in shares of Medtronic by 158.0% during the 4th quarter. Pin Oak Investment Advisors Inc. now owns 369 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 226 shares in the last quarter. Spectrum Management Group Inc. raised its stake in shares of Medtronic by 353.8% during the 1st quarter. Spectrum Management Group Inc. now owns 413 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 322 shares in the last quarter. Finally, Mackey Komara & Dankovich LLC purchased a new stake in shares of Medtronic during the 1st quarter worth about $38,000. 81.23% of the stock is owned by institutional investors.

A number of research analysts have recently commented on MDT shares. Oppenheimer set a $104.00 price objective on Medtronic and gave the company a “buy” rating in a report on Wednesday, February 20th. Wells Fargo & Co lowered their price objective on Medtronic from $101.00 to $100.00 and set a “market perform” rating on the stock in a report on Thursday, April 4th. Citigroup increased their price objective on Medtronic from $95.00 to $101.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Barclays reissued a “buy” rating and set a $104.00 price objective on shares of Medtronic in a report on Wednesday, February 20th. Finally, Northland Securities reissued a “hold” rating and set a $84.00 price objective on shares of Medtronic in a report on Monday, March 18th. Ten equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $103.39.



MDT opened at $90.81 on Friday. The company has a market capitalization of $117.71 billion, a price-to-earnings ratio of 19.04, a price-to-earnings-growth ratio of 2.18 and a beta of 0.78. The company has a current ratio of 2.36, a quick ratio of 1.92 and a debt-to-equity ratio of 0.47. Medtronic PLC has a 12-month low of $81.66 and a 12-month high of $100.15.

Medtronic (NYSE:MDT) last released its earnings results on Thursday, May 23rd. The medical technology company reported $1.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.47 by $0.07. The firm had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.12 billion. Medtronic had a return on equity of 13.85% and a net margin of 16.10%. The company’s revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm posted $1.42 EPS. Research analysts expect that Medtronic PLC will post 5.15 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/05/24/lee-danner-bass-inc-sells-303-shares-of-medtronic-plc-mdt.html.

Medtronic Company Profile

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Read More: Why is cost of goods sold important?

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.